AI brief of an SEC Form 8-K · Fox Corporation (Class A) (FOXA)

Fox revenue rises 2% to $5.18 billion, but quarterly profit falls

Mixed Impact 3 of 5 earnings Written later

Fox reported results for the quarter ended December 31, 2025, with revenue up 2% to $5.18 billion. Net income attributable to Fox stockholders fell to $229 million ($0.52 per share) from $373 million ($0.81 per share), and Adjusted EBITDA fell to $692 million from $781 million, so higher revenue did not translate into higher profit for shareholders.

Key points

  • Total revenues were $5.18 billion, up $104 million or 2% from the prior year quarter, with Cable Network Programming revenue up 5%.
  • Net income attributable to Fox stockholders was $229 million ($0.52 per share), versus $373 million ($0.81 per share) a year earlier.
  • Adjusted EPS was $0.82 versus $0.96 a year earlier; Adjusted EBITDA was $692 million versus $781 million, as higher expenses more than offset the revenue increase.
  • The Company declared a $0.28 per share dividend payable March 25, 2026, with a record date of March 4, 2026, and had about $3.6 billion remaining on its share repurchase authorization as of December 31, 2025.

The filing

CompanyFox Corporation (Class A) (FOXA)
Form8-K, current report
Filed with the SECFeb 4, 2026, 8:03 AM ET
Accession number0001628280-26-005277

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:10 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 04, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.